Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
accomplish, accrual, aggregate, allergy, alli, andAbreva, andBoost, andBoostrix, andFenbid, andForm, andHycamtin, andMekinist, andMepron, andPanadol, andPromacta, andSoriatane, andVentolin, andZinacef, April, arriving, attrition, Augmentin, Bactroban, Benlysta, Boostrix, bothXyzal, bound, BRAF, bribe, bribing, build, butAquafresh, byAbreva, bySeretide, Changsha, Chinese, clearance, clearer, cold, collaboration, commercialisation, committed, competing, Constellation, contrary, customary, deed, Dermatology, digit, discontinued, dose, dry, dyslipidemia, Ebola, eleven, Ellipta, exit, expertise, feel, fine, flu, Fluarix, FluLaval, fromTafinlar, fromVotrient, GSKCI, guilty, Hampton, Hepsera, highlighted, Hunan, IIa, IIb, improper, Indian, influenza, inSensodyne, Insufficient, Intermediate, Leo, life, likelihood, mainlyCombivir, marking, maximum, mechanism, melanoma, merit, metastatic, metered, Middle, milestone, Ministry, mission, modified, monotherapy, ofBreo, ofContac, official, ofLovaza, ofProlia, ofRelenza, ofVotrient, omitted, oncology, outbreak, outsourced, pandemic, Philip, Planet, powder, precise, preferred, primary, productsTafinlar, project, Province, Quadrivalent, rapidly, Rare, reassessment, recipient, regionTykerb, revaluation, reward, RMB, Rohner, Rotarix, SAPA, season, Serevent, shelving, smaller, solution, split, Stiefel, stockbuilding, strict, stronger, subsequent, subsequently, suspension, Synflorix, tail, theLucozade, thrombocytopenia, trending, unilaterally, unlawful, unwinding, upfront, uptake, Urs, verdict, Vesicare, voluntary, week, withAdvair, withSensodyne, workforce, Zeffix
Removed:
Robert, Wilson
Filing tables
Filing exhibits
GSK similar filings
Filing view
External links
Exhibit 15.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Form F-3 (Nos. 333-194744, 333-194744-01 and 333-194744-02) of GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GlaxoSmithKline Capital Inc., and in the Registration Statements on Form S-8 (Nos. 333-88966, 333-100388 and 333-162702) of GlaxoSmithKline plc of our report dated 27 February 2015, relating to the financial statements and the effectiveness of internal control over financial reporting of GlaxoSmithKline plc, which appears in this Annual Report on Form 20-F.
/s/ PricewaterhouseCoopers LLP |
PricewaterhouseCoopers LLP |
London, England |
27 February 2015